Overview

Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis

Status:
Unknown status

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

This study is aimed at assessing the kinetics of the ultrasound (US) response in DMARD-naive very early rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) and methotrexate (MTX).

Phase:

Phase 3

Details

Lead Sponsor:

Maria Stoenoiu

Treatments:

Methotrexate